Aug. 22 at 12:34 PM
$CRDL
CRDL & The New FDA Era under Trump & RFK Jr.
The vision is clear: affordable drugs, safer therapies, and real health outcomes. Both Trump and RFK Jr. want to move away from overpriced blockbusters, risky gene/cell therapies, and vaccines, and instead back medicines that are simple, scalable, and measurable.
How CardiolRx aligns:
• Affordable: oral, low-cost to produce, potential pricing near
$50,000/yr vs rilonacept at
$250,000+/yr.
• Safe: clean tolerability, no red flags.
• Objective: MRI-proven LV mass reduction in 12 weeks.
• Healthy focus: addresses inflammation at the root of myocarditis.
• Scalable: expansion into pericarditis, HFpEF/HFrEF, hypertrophy.
👉 At ~
$100M mcap, CRDL isn’t just undervalued — it’s the kind of therapy the new FDA era is designed to support
